Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study examined the safety profile of ritlecitinib, a drug for alopecia areata, and found that it does not cause significant QTc prolongation or severe lymphopenia, with no unique safety risks expected in adolescents.

This study found that Litfulo improved hair regrowth in patients aged 12 and older with severe alopecia areata but did not meaningfully improve anxiety or depression symptoms compared to placebo.

This review discusses the evolution of Cereblon ligands in PROTAC technology, highlighting chemical innovations that may enhance drug-likeness and applicability in protein degradation, while noting challenges and future research directions.

This study found that DVd therapy is at least as effective as VAD/VAd for treating multiple myeloma and causes fewer side effects and reduced hospital visits.

The review found that imiquimod is a promising non-invasive treatment for HPV-related neoplasias, particularly effective for vulvar lesions, but notes that more research is needed to optimize its use.

In this study, researchers observed that phospholipid-calcium carbonate hybrid nanoparticles effectively delivered Tofacitinib citrate topically, which significantly inhibited hair follicle apoptosis and promoted hair growth in a mouse model of chemotherapy-induced alopecia, compared to a traditional Tofacitinib solution.

This review highlights the potential of PROTAC technology in drug discovery for previously undruggable targets, particularly in cancer therapy, while emphasizing the urgent need to discover more E3 ligase recruiters to optimize targeted protein degradation.

This review discusses the potential of combined therapy with WP 631 and epothilone B for ovarian cancer, but reports no new clinical results.

This systematic review and meta-analysis found that bimatoprost, especially when used with NB-UVB phototherapy, FxCO2 laser, or mometasone, may be an effective and well-tolerated treatment option for vitiligo, achieving significant patient satisfaction and repigmentation, despite some limitations like small sample sizes and high costs.

In this study, researchers described ONCO-NK-TRANSITION-GM1, a cancer therapy that's manufacturable with current pharmaceutical methods, showing a 60-80% complete response rate across various cancer types and costing $50 per dose, providing a more accessible alternative to existing treatments.

This study observed that patients with alopecia areata taking ritlecitinib reported higher satisfaction with hair growth after 24 and 48 weeks compared to those taking a placebo, aligning with improvements in hair growth noted by doctors.

This review discusses recent advancements in targeted therapies for vitiligo, including JAK inhibitors and mesenchymal stem cells, and highlights the need for further research.

This study found that oral administration of Flammulina velutipes polysaccharide reduced tumor volume and improved survival in mice by modulating macrophage polarization and enhancing antitumor immune responses.

This source concludes that repurposing existing drugs, such as using metformin with other treatments in advanced non-small cell lung cancer, may enhance cancer patient outcomes, although various technical and legal challenges need addressing.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

This study found that microneedling combined with calcipotriol plus betamethasone was more effective in treating vitiligo than microneedling with tacrolimus, particularly in difficult-to-treat areas.

In this real-world study, 27% of alopecia areata patients treated with ritlecitinib achieved a target SALT score, a result consistent with clinical trial findings, highlighting the value of patient-reported outcomes in understanding treatment impact beyond traditional measures.

In this study, topical tofacitinib significantly promoted hair regrowth in mice, outpacing both minoxidil and controls over 21 days, with findings suggesting increased VEGF levels and decreased inflammation as possible mechanisms.

This study introduces a novel pro-drug formulation of all-trans retinoic acid that reduces skin inflammation and achieves sustained drug release over several days compared to traditional methods.

This study found that both tofacitinib and methotrexate effectively reduced hair loss and psychological distress in patients with moderate-to-severe alopecia areata, but tofacitinib showed much greater efficacy. Both treatments had similar safety profiles, with no serious adverse effects reported.

This study found that nearly 40% of Hodgkin’s Lymphoma patients who received Brentuximab Vedotin with AVD chemotherapy experienced persistent alopecia more than two years after treatment, leading to significant psychosocial consequences such as reduced self-confidence and emotional distress.

In this study, researchers found that applying topical aprepitant, which blocks substance P receptors, significantly reduced facial dermatitis and hair loss in rats experiencing erlotinib-induced skin side effects, highlighting the neurogenic inflammation's role and the protective effect of ROS inhibition.

This study found that patients with severe alopecia areata are willing to accept increased risks of serious infection, cancer, and blood clots when opting for a higher dose of ritlecitinib, valuing the potential for greater hair regrowth efficacy compared to a lower dose.

This study identified several anticancer drugs, including vinblastine and bortezomib, that significantly increase the risk of developing chemotherapy-induced peripheral neuropathy, with variations in time-to-onset among different drug categories.

This study found that valproic acid promoted hair re-growth in C3H mice by activating the Wnt/β-catenin pathway, suggesting its potential as a treatment for alopecia.

This study found that the TYK2 inhibitor deucravacitinib did not significantly improve hair regrowth in patients with alopecia areata compared to placebo, suggesting it may not be effective for this condition. No new safety issues were identified.

This study found that the serine protease inhibitor ONO-3403 significantly suppressed tumor growth in mice with induced squamous cell carcinoma without apparent side effects, suggesting its potential for cancer treatment.

This research found that combining a 308-nm excimer laser with oral compound glycyrrhizin and topical 0.03% tacrolimus was more effective for treating pediatric facial and cervical vitiligo, resulting in faster and higher rates of repigmentation with minimal adverse effects compared to glycyrrhizin and tacrolimus alone.

This study reports that ritlecitinib was prescribed to a diverse group of patients, including adolescents and adults with and without prior treatment for Alopecia Areata, in the first three months after FDA approval, potentially expanding care options for this condition.

This study suggests that cutaneous adverse reactions to bortezomib and lenalidomide are more frequent than reported, impacting patients' quality of life and may require dermatological consultation for proper management.